文献速递胃肠动力与功能性疾病

利福霉素SV-MMX 600毫克片每日三次或两次给药治疗腹泻型肠易激综合征疗效与安全性的II期、多中心、随机、双盲、安慰剂对照、概念验证研究

A Phase II, Multicentric, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
PubMed 文献 · Am J Gastroenterol · 2024-11-26

该II期多中心随机双盲安慰剂对照研究纳入279例罗马IV标准腹泻型肠易激综合征患者,比较利福霉素SV-MMX 600毫克每日两次(1200毫克/日)或每日三次(1800毫克/日)与安慰剂治疗2周的疗效。主要终点为第一治疗周应答率,每日两次组25.00%高于每日三次组12.35%和安慰剂组9.47%;每日两次组较安慰剂的校正比值比为3.26(95%CI 1.39-7.67;P=0.007)。

要点

  • 每日两次组第一周应答率25.00%,高于每日三次组12.35%和安慰剂组9.47%。
  • 每日两次组较安慰剂的校正比值比为3.26(95%CI 1.39-7.67;P=0.007)。
  • 治疗后第一个月每日两次组总体应答率64.2%,高于安慰剂组46.6%。

核心结论

  • 利福霉素SV-MMX 600毫克每日两次在第一治疗周比安慰剂和每日三次给药更有效。
  • 治疗结束后两个月,利福霉素SV-MMX 600毫克每日两次比安慰剂提供更多总体症状缓解。

研究设计与样本

  • II期、多中心、随机、双盲、安慰剂对照、概念验证研究。
  • 纳入罗马IV标准腹泻型肠易激综合征患者。
  • 患者随机接受利福霉素SV-MMX 600毫克每日两次(1200毫克/日)或每日三次(1800毫克/日)或安慰剂治疗2周。
  • 共279例患者随机(意向治疗集),其中264例纳入全分析集。
  • 主要终点为全分析集第一治疗周应答率,应答定义为平均腹痛下降≥30%且每日报告的6型或7型粪便天数减少≥50%。

主要发现

  • 全分析集和意向治疗集中,每日两次组22/88(25.00%)达到主要终点,高于每日三次组10/81(12.35%)和安慰剂组9/95(9.47%)。
  • 每日两次组较安慰剂的校正比值比为3.26(95%CI 1.39-7.67;P=0.007)。
  • 每日三次组较每日两次组的校正比值比为0.40(95%CI 0.17-0.92;P=0.031)。
  • 治疗后第一个月,每日两次组月度总体应答率为64.2%,高于安慰剂组的46.6%,校正比值比为2.14(95%CI 1.15-4.00;P=0.0173)。
  • 治疗后前两个月,每日两次组月度总体应答率高于安慰剂组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Treatment with nonresorbable antibiotics is effective in diarrhea-predominant irritable bowel syndrome (IBS-D). Multimatrix (MMX) formulations ensure targeted drug delivery to the mid-distal small bowel and colon-traditionally considered the origin of IBS symptoms. To assess the efficacy of rifamycin SV-MMX for the treatment of IBS-D. METHODS: Randomized controlled trial in patients with IBS-D (Rome IV). Patients received rifamycin SV-MMX 600 mg (b.i.d = 1200 mg/d or t.i.d = 1800 mg/d) or placebo for 2 weeks. Primary end point was responder rate in the first treatment week on the full analysis set (FAS). Response was defined as decrease in average abdominal pain ≥ 30% AND ≥50% reduction of days with stool type 6 or 7 based on daily reporting. RESULTS: A total of 279 patients were randomized (=ITT), and 264 of were included in the FAS. More patients with rifamycin SV-MMX b.i.d (22/88, 25.00%) met the primary end point than t.i.d (10/81, 12.35%) or placebo (9/95, 9.47%) in both FAS and ITT. Adjusted odds ratio (AOR) for b.i.d. vs placebo was 3.26 (95% confidence interval (CI): 1.39-7.67; P = 0.007) and for t.i.d. vs b.i.d. 0.40 (95% CI: 0.17-0.92; P = 0.031). After treatment, the percentage of monthly global responders was higher in the b.i.d. group vs placebo in the first month (64.2% vs 46.6%, adjusted odds ratio = 2.14 95% CI: 1.15; 4.00; P = 0.0173) and first 2 months. DISCUSSION: Rifamycin SV-MMX 600 mg b.i.d. was more effective than placebo and t.i.d. dosing in the first week of treatment. Two months after treatment, rifamycin SV-MMX 600 mg b.i.d. provided more global symptom relief than placebo.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Balsiger LM, Santos J, Serra J, et al. A Phase II, Multicentric, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol. 2024. PMID: 39589118. doi:10.14309/ajg.0000000000003236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。